HALO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $29,884,783.11

Halozyme Therapeutics Insider Trading History Chart

Halozyme Therapeutics Share Price & Price History

^$128.95

▼ -1.96 (-1.50%)

As of 11/2/2026 04:00 PM ET

Days: 30 | 90 | 365

Halozyme Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/8/2026	Helen Torley	CEO	Sell	20,000	$109.40	$2,188,000.00	767,780
10/6/2026	Helen Torley	CEO	Sell	20,000	$109.58	$2,191,600.00	767,780
10/1/2026	Matthew L. Posard	Director	Sell	5,230	$108.54	$567,664.20	53,609
9/16/2026	Matthew L. Posard	Director	Sell	18,996	$107.74	$2,046,629.04	58,839
9/11/2026	Helen Torley	CEO	Sell	20,000	$107.24	$2,144,800.00	767,780
9/9/2026	Helen Torley	CEO	Sell	20,000	$107.43	$2,148,600.00	767,780
8/18/2026	Helen Torley	CEO	Sell	20,000	$104.18	$2,083,600.00	767,780
8/10/2026	Bernadette Connaughton	Director	Sell	1,626	$102.80	$167,152.80	40,418
7/8/2026	Helen Torley	CEO	Sell	1,923	$79.77	$153,397.71	767,780
7/1/2026	Bernadette Connaughton	Director	Sell	1,625	$76.71	$124,653.75	42,044
6/29/2026	Mahesh Krishnan	Director	Sell	7,304	$75.00	$547,800.00	14,462
6/3/2026	Helen Torley	CEO	Sell	10,000	$69.07	$690,700.00	767,780
6/1/2026	Bernadette Connaughton	Director	Sell	1,625	$66.21	$107,591.25	43,669
6/1/2026	Helen Torley	CEO	Sell	20,000	$67.58	$1,351,600.00	767,780
5/13/2026	Helen Torley	CEO	Sell	10,000	$69.19	$691,900.00	767,780
5/12/2026	Helen Torley	CEO	Sell	20,000	$71.75	$1,435,000.00	767,780
5/1/2026	Bernadette Connaughton	Director	Sell	1,625	$63.48	$103,155.00	38,498
4/6/2026	Helen Torley	CEO	Sell	10,000	$63.50	$635,000.00	767,780
4/2/2026	Helen Torley	CEO	Sell	20,000	$64.24	$1,284,800.00	767,780
3/10/2026	Cortney Caudill	COO	Sell	8,857	$67.64	$599,087.48	7,055
3/9/2026	Cortney Caudill	COO	Sell	20,000	$67.80	$1,356,000.00	14,366
3/4/2026	Helen Torley	CEO	Sell	10,000	$70.21	$702,100.00	767,780
3/2/2026	Helen Torley	CEO	Sell	20,000	$69.69	$1,393,800.00	767,780
2/5/2026	Helen Torley	CEO	Sell	10,000	$78.64	$786,400.00	708,719
2/3/2026	Helen Torley	CEO	Sell	20,000	$76.12	$1,522,400.00	708,719
1/5/2026	Bernadette Connaughton	Director	Sell	2,000	$70.25	$140,500.00	40,123
12/1/2025	Bernadette Connaughton	Director	Sell	829	$71.60	$59,356.40	42,123
12/1/2025	Helen Torley	CEO	Sell	16,569	$68.92	$1,141,935.48	708,719
11/11/2025	Helen Torley	CEO	Sell	20,000	$69.13	$1,382,600.00	733,719
11/10/2025	Bernadette Connaughton	Director	Sell	2,000	$68.48	$136,960.00	42,952
11/1/2025	Cortney Caudill	COO	Sell	4,263	$65.19	$277,904.97	12,737
10/3/2025	Helen Torley	CEO	Sell	20,000	$69.03	$1,380,600.00	733,719
10/1/2025	Bernadette Connaughton	Director	Sell	2,000	$75.24	$150,480.00	44,952
10/1/2025	Helen Torley	CEO	Sell	20,000	$75.35	$1,507,000.00	733,719
9/22/2025	Nicole Labrosse	CFO	Sell	2,227	$77.95	$173,594.65	22,079
9/10/2025	Nicole Labrosse	CFO	Sell	20,000	$75.71	$1,514,200.00	24,306
9/3/2025	Helen Torley	CEO	Sell	20,000	$74.44	$1,488,800.00	733,719
9/2/2025	Bernadette Connaughton	Director	Sell	4,000	$73.68	$294,720.00	46,952
8/12/2025	Helen Torley	CEO	Sell	20,000	$63.51	$1,270,200.00	733,719
7/9/2025	Helen Torley	CEO	Sell	20,000	$56.43	$1,128,600.00	733,719
6/24/2025	Helen Torley	CEO	Sell	20,000	$53.73	$1,074,600.00	733,719
6/20/2025	Helen Torley	CEO	Sell	20,000	$52.96	$1,059,200.00	733,719
4/28/2025	Jeffrey William Henderson	Director	Sell	4,497	$60.37	$271,483.89	28,611
4/1/2025	Jeffrey William Henderson	Director	Sell	503	$64.05	$32,217.15	33,108
3/3/2025	Jeffrey William Henderson	Director	Sell	5,000	$58.69	$293,450.00	33,611
2/27/2025	Michael J. LaBarre	SVP	Sell	1,697	$58.28	$98,901.16	173,756
2/25/2025	Michael J. LaBarre	SVP	Sell	10,000	$58.05	$580,500.00	185,453
2/3/2025	Jeffrey William Henderson	Director	Sell	5,000	$56.30	$281,500.00	38,611
1/6/2025	Jeffrey William Henderson	Director	Sell	10,000	$50.01	$500,100.00	43,611
10/16/2024	Michael J. LaBarre	SVP	Sell	10,000	$53.26	$532,600.00	173,756
10/9/2024	Helen Torley	CEO	Sell	10,000	$52.58	$525,800.00	676,744
9/25/2024	Helen Torley	CEO	Sell	10,000	$56.34	$563,400.00	676,744
9/18/2024	Michael J. LaBarre	SVP	Sell	10,000	$62.03	$620,300.00	173,756
9/12/2024	Helen Torley	CEO	Sell	10,000	$59.20	$592,000.00	676,744
9/10/2024	Helen Torley	CEO	Sell	10,000	$59.09	$590,900.00	676,744
8/21/2024	Michael J. LaBarre	SVP	Sell	10,000	$61.75	$617,500.00	168,176
8/14/2024	Matthew L. Posard	Director	Sell	9,881	$57.70	$570,133.70	69,874
8/12/2024	Matthew L. Posard	Director	Sell	10,000	$55.72	$557,200.00	89,755
7/24/2024	Michael J. LaBarre	SVP	Sell	10,000	$55.12	$551,200.00	168,176
7/22/2024	Nicole Labrosse	CFO	Sell	5,000	$53.93	$269,650.00	15,480
6/27/2024	Nicole Labrosse	CFO	Sell	10,000	$51.93	$519,300.00	15,480
6/11/2024	Matthew L. Posard	Director	Sell	10,000	$50.01	$500,100.00	109,755
5/22/2024	Michael J. LaBarre	SVP	Sell	10,000	$45.38	$453,800.00	168,176
4/17/2024	Michael J. LaBarre	SVP	Sell	10,000	$38.49	$384,900.00	168,176
3/12/2024	Michael J. LaBarre	SVP	Sell	10,000	$41.64	$416,400.00	156,558
2/28/2024	Michael J. LaBarre	SVP	Sell	10,000	$39.55	$395,500.00	156,558
12/12/2023	Michael J. LaBarre	SVP	Sell	10,000	$39.63	$396,300.00	151,911

SEC Filings (Institutional Ownership Changes) for Halozyme Therapeutics (NASDAQ:HALO)

97.79% of Halozyme Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Halozyme Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
10/31/2026	Boston Trust Walden Corp	1,035,813	$114.35M	0.9%	-4.4%	0.913%
10/31/2026	Chicago Partners Investment Group LLC	1,616	$0.20M	0.0%	N/A	0.001%
10/31/2026	Verity Asset Management Inc.	49,295	$5.44M	2.1%	-11.2%	0.043%
10/30/2026	Compass Financial Management LLC	3,164	$0.35M	0.0%	N/A	0.003%
10/30/2026	Provenance Wealth Advisors LLC	3,209	$0.35M	0.0%	N/A	0.003%
10/30/2026	Oregon Public Employees Retirement Fund	23,462	$2.59M	0.0%	-4.5%	0.021%
10/30/2026	Gallacher Capital Management LLC	2,972	$0.33M	0.3%	-43.5%	0.003%
10/30/2026	Torray Investment Partners LLC	38,540	$4.26M	0.6%	-0.4%	0.034%
10/30/2026	Keeler Thomas Management LLC	17,722	$1.96M	0.8%	-2.3%	0.016%
10/29/2026	Welch Group LLC	3,200	$0.35M	0.0%	+18.5%	0.003%
10/29/2026	Virtue Capital Management LLC	12,270	$1.36M	0.2%	N/A	0.011%
10/29/2026	Sumitomo Mitsui Trust Group Inc.	11,300	$1.25M	0.0%	+4.6%	0.010%
10/29/2026	Mirae Asset Global Investments Co. Ltd.	5,800	$0.64M	0.0%	N/A	0.005%
10/29/2026	Profund Advisors LLC	22,633	$2.50M	0.1%	+4.1%	0.020%
10/29/2026	ProShare Advisors LLC	8,248	$0.91M	0.0%	-3.7%	0.007%
10/29/2026	Vise Technologies Inc.	12,645	$1.40M	0.0%	+33.1%	0.011%
10/29/2026	MGO One Seven LLC	6,896	$0.76M	0.0%	-21.0%	0.006%
10/29/2026	State of Wyoming	1,973	$0.22M	0.0%	-69.9%	0.002%
10/28/2026	VIRGINIA RETIREMENT SYSTEMS ET Al	28,700	$3.17M	0.0%	+119.1%	0.025%
10/28/2026	Founders Financial Securities LLC	8,667	$0.96M	0.0%	N/A	0.008%
10/28/2026	Choreo LLC	3,794	$0.42M	0.0%	-5.4%	0.003%
10/28/2026	China Universal Asset Management Co. Ltd.	20,709	$2.31M	0.1%	+9.7%	0.000%
10/28/2026	Childress Capital Advisors LLC	2,006	$0.22M	0.0%	N/A	0.000%
10/28/2026	BOKF NA	15,811	$1.75M	0.0%	+1.8%	0.000%
10/28/2026	Hanseatic Management Services Inc.	2,745	$0.30M	0.2%	N/A	0.000%
10/28/2026	North Dakota State Investment Board	3,598	$0.40M	0.0%	+4.3%	0.000%
10/27/2026	Victory Financial Group LLC	3,169	$0.35M	0.0%	-69.9%	0.003%
10/27/2026	Roman Butler Fullerton & Co.	3,989	$0.49M	0.1%	N/A	0.004%
10/26/2026	Oppenheimer & Co. Inc.	22,013	$2.43M	0.0%	+39.6%	0.019%
10/26/2026	Verdence Capital Advisors LLC	15,172	$1.68M	0.1%	+21.5%	0.013%
10/26/2026	Westover Capital Advisors LLC	2,025	$0.22M	0.0%	N/A	0.002%
10/24/2026	Apollon Wealth Management LLC	5,296	$0.59M	0.0%	N/A	0.005%
10/24/2026	Hilton Head Capital Partners LLC	300	$33K	0.0%	N/A	0.000%
10/24/2026	Samalin Investment Counsel LLC	2,082	$0.23M	0.1%	N/A	0.002%
10/23/2026	Radnor Capital Management LLC	5,638	$0.62M	0.1%	+27.0%	0.005%
10/23/2026	Brucke Financial Inc.	2,835	$0.31M	0.1%	+9.3%	0.002%
10/23/2026	Signaturefd LLC	1,755	$0.19M	0.0%	+24.7%	0.002%
10/23/2026	Simplicity Wealth LLC	2,962	$0.33M	0.0%	N/A	0.003%
10/23/2026	Evergreen Capital Management LLC	4,973	$0.55M	0.0%	-10.2%	0.004%
10/23/2026	Gibbs Wealth Management	19,020	$2.10M	0.2%	+140.0%	0.017%
10/23/2026	Tectonic Advisors LLC	19,360	$2.14M	0.1%	+20.9%	0.017%
10/23/2026	Fifth Third Wealth Advisors LLC	4,515	$0.50M	0.0%	+3.5%	0.004%
10/23/2026	Sterling Capital Management LLC	5,199	$0.57M	0.0%	+570.8%	0.005%
10/23/2026	James Investment Research Inc.	29,436	$3.25M	0.4%	+10.8%	0.026%
10/23/2026	Inspire Investing LLC	28,340	$3.13M	0.1%	N/A	0.025%
10/22/2026	Yousif Capital Management LLC	24,929	$2.75M	0.0%	-10.1%	0.022%
10/22/2026	Brookstone Capital Management	7,408	$0.82M	0.0%	-32.8%	0.007%
10/22/2026	Root Financial Partners LLC	739	$82K	0.0%	N/A	0.001%
10/22/2026	SBI Securities Co. Ltd.	898	$99K	0.0%	+78.2%	0.001%
10/22/2026	Cardinal Capital Management	29,788	$3.29M	0.4%	+6.1%	0.026%
10/21/2026	Smith Shellnut Wilson LLC ADV	2,420	$0.27M	0.1%	N/A	0.002%
10/21/2026	Crossmark Global Holdings Inc.	3,674	$0.41M	0.0%	+6.9%	0.003%
10/21/2026	Quadrant Capital Group LLC	8,958	$0.98M	0.0%	+2.0%	0.008%
10/21/2026	Innova Wealth Partners	5,516	$0.61M	0.2%	+4.3%	0.005%
10/21/2026	Nisa Investment Advisors LLC	24,512	$2.71M	0.0%	+640.5%	0.022%
10/21/2026	Diversify Advisory Services LLC	37,945	$4.61M	0.1%	+11.7%	0.033%
10/20/2026	AMI Asset Management Corp	8,261	$0.91M	0.1%	-32.0%	0.007%
10/20/2026	Prime Capital Investment Advisors LLC	2,561	$0.28M	0.0%	N/A	0.002%
10/20/2026	Net Worth Advisory Group	7,634	$0.82M	0.2%	+4.8%	0.007%
10/20/2026	CWA Asset Management Group LLC	16,829	$1.86M	0.1%	+60.3%	0.015%
10/19/2026	Novem Group	3,067	$0.34M	0.0%	+16.5%	0.003%
10/19/2026	Fairvoy Private Wealth LLC	10,892	$1.20M	0.2%	N/A	0.010%
10/17/2026	IFP Advisors Inc	5,022	$0.55M	0.0%	+27.5%	0.004%
10/17/2026	Encompass More Asset Management	3,161	$0.35M	0.1%	-17.2%	0.003%
10/17/2026	USA Financial Formulas	1,394	$0.15M	0.0%	N/A	0.001%
10/16/2026	Vontobel Holding Ltd.	4,014	$0.44M	0.0%	-3.5%	0.004%
10/16/2026	Cyndeo Wealth Partners LLC	1,887	$0.21M	0.0%	N/A	0.002%
10/16/2026	Shelton Wealth Management LLC	15,686	$1.73M	0.7%	-25.5%	0.014%
10/15/2026	Assenagon Asset Management S.A.	396,866	$43.81M	0.0%	-60.2%	0.350%
10/15/2026	Brindle & Bay Financial Advisors LLC	2,090	$0.23M	0.1%	-26.8%	0.002%
10/15/2026	State of Alaska Department of Revenue	141,555	$15.63M	0.1%	-0.6%	0.125%
10/15/2026	Mather Group LLC.	414	$46K	0.0%	+48.9%	0.000%
10/14/2026	Koa Wealth Management LLC	92,992	$10.27M	7.0%	-1.4%	0.082%
10/14/2026	First Citizens Bank & Trust Co.	3,617	$0.40M	0.0%	-59.5%	0.003%
10/14/2026	Focus Financial Network Inc.	3,368	$0.37M	0.0%	-7.8%	0.003%
10/14/2026	Signal Advisors Wealth LLC	7,696	$0.85M	0.0%	N/A	0.007%
10/14/2026	Ifrah Financial Services Inc.	6,848	$0.76M	0.2%	-1.8%	0.006%
10/14/2026	B. Riley Wealth Advisors Inc.	2,103	$0.23M	0.0%	N/A	0.002%
10/13/2026	Cooper Investors PTY Ltd.	65,933	$7.28M	3.9%	+19.8%	0.058%
10/13/2026	NorthCrest Asset Manangement LLC	57,661	$6.33M	0.1%	+27.7%	0.051%
10/9/2026	GK Wealth Management LLC	1,608	$0.18M	0.1%	N/A	0.001%
10/9/2026	Balefire LLC	3,227	$0.36M	0.1%	+9.9%	0.003%
10/9/2026	Wedmont Private Capital	2,673	$0.29M	0.0%	N/A	0.002%
10/9/2026	Journey Retirement Planning & Investment Management LLC	3,008	$0.33M	0.2%	N/A	0.003%
10/9/2026	Legacy Wealth Asset Management LLC	5,210	$0.58M	0.1%	+38.5%	0.005%
10/9/2026	Monument Capital Management	28,511	$3.15M	0.7%	N/A	0.025%
10/9/2026	GAMMA Investing LLC	5,493	$0.61M	0.0%	+22.4%	0.005%
10/8/2026	Farther Finance Advisors LLC	11,074	$1.22M	0.0%	-1.5%	0.010%
10/8/2026	CoreCap Advisors LLC	303	$33K	0.0%	+98.0%	0.000%
10/8/2026	Gradient Investments LLC	14,952	$1.65M	0.0%	-9.0%	0.013%
10/8/2026	Whalen Wealth Management Inc.	5,275	$0.58M	0.3%	-31.4%	0.005%
10/7/2026	MRA Advisory Group	6,713	$0.74M	0.3%	N/A	0.006%
10/6/2026	Juncture Wealth Strategies LLC	11,625	$1.28M	0.3%	-2.0%	0.010%
10/6/2026	Congress Asset Management Co.	2,281,615	$251.89M	1.6%	+85.6%	2.010%
10/5/2026	Pacific Wealth Management	2,184	$0.24M	0.2%	-59.6%	0.002%
10/5/2026	Argent Capital Management LLC	5,079	$0.56M	0.0%	-7.0%	0.004%
10/5/2026	Collective Family Office LLC	6,313	$0.70M	0.1%	-22.2%	0.006%
10/5/2026	MassMutual Private Wealth & Trust FSB	470	$52K	0.0%	-21.9%	0.000%
9/29/2026	Cim Investment Management Inc.	9,121	$0.71M	0.2%	+7.4%	0.008%
9/23/2026	QRG Capital Management Inc.	6,626	$0.52M	0.0%	+11.1%	0.006%

Data available starting January 2016

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Range

Now: $128.95

$127.52

$131.89

50 Day Range

MA: $113.70

$105.35

$131.18

52 Week Range

Now: $128.95

$61.22

$134.00

Volume

3,363,979 shs

Average Volume

1,951,852 shs

Market Capitalization

$14.64 billion

P/E Ratio

38.49

Dividend Yield

N/A

Beta

0.92

Who are the company insiders with the largest holdings of Halozyme Therapeutics?: Halozyme Therapeutics' top insider shareholders include:
Randal J Kirk (Major Shareholder)
Helen Torley (CEO)
Kathryn Falberg (Director)
Kenneth J Kelley (Director)
Robert Engler (Director)
Connie Matsui (Director)
Michael J Labarre (SVP)
John Stuart Patton (Director)
Matthew L Posard (Director)
Jeffrey William Henderson (Director)
Learn More about top insider investors at Halozyme Therapeutics.
Who are the major institutional investors of Halozyme Therapeutics?: Halozyme Therapeutics' top institutional investors include:
Congress Asset Management Co. — 2.01%
Boston Trust Walden Corp — 0.91%
Assenagon Asset Management S.A. — 0.35%
State of Alaska Department of Revenue — 0.12%
Koa Wealth Management LLC — 0.08%
Cooper Investors PTY Ltd. — 0.06%
Learn More about top institutional investors of Halozyme Therapeutics stock.
Which major investors are selling Halozyme Therapeutics stock?: Within the last quarter, HALO stock was sold by these institutional investors:
Assenagon Asset Management S.A.
Boston Trust Walden Corp
Victory Financial Group LLC
Verity Asset Management Inc.
Shelton Wealth Management LLC
First Citizens Bank & Trust Co.
State of Wyoming
AMI Asset Management Corp
In the last year, company insiders that have sold Halozyme Therapeutics company stock include:
Helen Torley (CEO)
Matthew L Posard (Director)
Bernadette Connaughton (Director)
Mahesh Krishnan (Director)
Cortney Caudill (COO)
Learn More investors selling Halozyme Therapeutics stock.
Which major investors are buying Halozyme Therapeutics stock?: Within the last quarter, HALO stock was acquired by institutional investors including:
Congress Asset Management Co.
Monument Capital Management
Inspire Investing LLC
Nisa Investment Advisors LLC
VIRGINIA RETIREMENT SYSTEMS ET Al
NorthCrest Asset Manangement LLC
Virtue Capital Management LLC
Gibbs Wealth Management